Age and kidney function are the primary correlates of fasting plasma total homocysteine levels in non-diabetic and diabetic adults. Results from the 1999-2002 National Health and Nutrition Examination Survey

Nutrition and Metabolism

Volumn 2, Issue , 2005, Pages

  Duncan, Glen E ^a   Li, Sierra M ^a   Zhou, Xiao Hua ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b VA PUGET SOUND HEALTH CARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HOMOCYSTEINE;

ADULT; AGE; ANAMNESIS; ARTICLE; BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; CREATININE CLEARANCE; DATA ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HEALTH SURVEY; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITION; PREDICTION; SELF REPORT;

EID: 23044480082     PISSN: 17437075     EISSN: None     Source Type: Journal    
DOI: 10.1186/1743-7075-2-13     Document Type: Article

References (29)

1. Kannel WB, McGee DL: Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care 1979, 2:120-126.
2. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR: Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 1990, 120:672-676.
3. Stamler J, Vaccaro O, Neaton JD, Wentworth D: Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993, 16:434-444.
4. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care 1998, 21:1551-1559.
5. Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE: Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002, 25:1129-1134.
6. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG: A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. Jama 1995, 274:1049-1057.
7. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB: Homocyst(e)ine and cardiovascular disease: a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies. Int J Epidemiol 2002, 31:59-70.
8. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. Jama 2002, 288:2015-2022.
9. Hoogeveen EK, Kostense PJ, Beks PJ, Mackaay AJ, Jakobs C, Bouter LM, Heine RJ, Stehouwer CD: Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus: a population-based study. Arterioscler Thromb Vasc Biol 1998, 18:133-138.
10. Hoogeveen EK, Kostense PJ, Jakobs C, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD: Hyperhomocysteinemia increases risk of death, especially in type 2 diabetes : 5-year follow-up of the Hoorn Study. Circulation 2000, 101:1506-1511.
11. Becker A, Kostense PJ, Bos G, Heine RJ, Dekker JM, Nijpels G, Bouter LM, Stehouwer CD: Hyperhomocysteinaemia is associated with coronary events in type 2 diabetes. J Intern Med 2003, 253:293-300.
12. Araki A, Sako Y, Ito H: Plasma homocysteine concentrations in Japanese patients with non-insulin-dependent diabetes mellitus: effect of parenteral methylcobalamin treatment. Atherosclerosis 1993, 103:149-157.
13. Drzewoski J, Czupryniak L, Chwatko G, Bald E: Hyperhomocysteinemia in poorly controlled type 2 diabetes patients. Diabetes Nutr Metab 2000, 13:319-324.
14. Passaro A, Calzoni F, Volpato S, Nora ED, Pareschi PL, Zamboni PF, Fellin R, Solini A: Effect of metabolic control on homocysteine levels in type 2 diabetic patients: a 3-year follow-up. J Intern Med 2003, 254:264-271.
15. Hultberg B, Agardh CD, Agardh E, Lovestam-Adrian M: Poor metabolic control, early age at onset, and marginal folate deficiency are associated with increasing levels of plasma homocysteine in insulin-dependent diabetes mellitus. A fiveyear follow-up study. Scand J Clin Lab Invest 1997, 57:595-600.
16. Cronin CC, McPartlin JM, Barry DG, Ferriss JB, Scott JM, Weir DG: Plasma homocysteine concentrations in patients with type 1 diabetes. Diabetes Care 1998, 21:1843-1847.
17. Dicker-Brown A, Fonseca VA, Fink LM, Kern PA: The effect of glucose and insulin on the activity of methylene tetrahydrofolate reductase and cystathionine-beta-synthase: studies in hepatocytes. Atherosclerosis 2001, 158:297-301.
18. Cockcroft DW, Gault HM: Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-41.
19. Clinical Practice Recommendations 2005. Diabetes Care 2005, 28 Suppl 1:S1-79.
20. Fonseca VA, Mudaliar S, Schmidt B, Fink LM, Kern PA, Henry RR: Plasma homocysteine concentrations are regulated by acute hyperinsulinemia in nondiabetic but not type 2 diabetic subjects. Metabolism 1998, 47:686-689.
21. Pouwels MJ, Den Heijer M, Blom HJ, Tack CJ, Hermus AR: Improved insulin sensitivity and metabolic control in type 2 diabetes does not influence plasma homocysteine. Diabetes Care 2003, 26:1637-1639.
22. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G: National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 2003, 139:137-147.
23. Friedman AN, Bostom AG, Selhub J, Levey AS, Rosenberg IH: The kidney and homocysteine metabolism. J Am Soc Nephrol 2001, 12:2181-2189.
24. Wollesen F, Brattstrom L, Refsum H, Ueland PM, Berglund L, Berne C: Plasma total homocysteine and cysteine in relation to glomerular filtration rate in diabetes mellitus. Kidney Int 1999, 55:1028-1035.
25. Stabler SP, Estacio R, Jeffers BW, Cohen JA, Allen RH, Schrier RW: Total homocysteine is associated with nephropathy in noninsulin-dependent diabetes mellitus. Metabolism 1999, 48:1096-1101.
26. Davies L, Wilmshurst EG, McElduff A, Gunton J, Clifton-Bligh P, Fulcher GR: The relationship among homocysteine, creatinine clearance, and albuminuria in patients with type 2 diabetes. Diabetes Care 2001, 24:1805-1809.
27. Nygard O, Vollset SE, Refsum H, Stensvold I, Tverdal A, Nordrehaug JE, Ueland M, Kvale G: Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. Jama 1995, 274:1526-1533.
28. Fonseca V, Guba SC, Fink LM: Hyperhomocysteinemia and the endocrine system: implications for atherosclerosis and thrombosis. Endocr Rev 1999, 20:738-759.
29. Russo GT, Di Benedetto A, Giorda C, Alessi E, Crisafulli G, Ientile R, Di Cesare E, Jacques PF, Raimondo G, Cucinotta D: Correlates of total homocysteine plasma concentration in type 2 diabetes. Eur J Clin Invest 2004, 34:197-204.